

# The anti-endotoxin agent, taurolidine, potentially reduces ischaemia-reperfusion injury through its metabolite taurine

**Submission date**

16/06/2009

**Recruitment status**

No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**

21/07/2009

**Overall study status**

Completed

☐ Statistical analysis plan

☐ Results

**Last Edited**

21/07/2009

**Condition category**

Injury, Occupational Diseases, Poisoning

☐ Individual participant data

☐ Record updated in last year

**Plain English summary of protocol**

Not provided at time of registration

## Contact information

**Type(s)**

Scientific

**Contact name**

Prof Paul Redmond

**Contact details**

Department of Surgery  
Cork University Hospital  
Wilton  
Cork  
Ireland  
-

## Additional identifiers

**Protocol serial number**

N/A

## Study information

**Scientific Title**

An investigation into the efficacy of the anti-endotoxin agent, taurolidine in the attenuation of the post-reperfusion sequelae in patients subjected to cardio-pulmonary bypass: a double-blinded randomised clinical trial

### **Study objectives**

Peri-operative administration of taurolidine decreases inflammatory response to cardiopulmonary bypass (CPB) and attenuates ischaemia-reperfusion (I-R) injury.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics Committee of University College Cork (Ireland) granted approval on the 5th March 1999, as well as the Irish Medicines Board (IMB)

### **Study design**

Double-blinded randomised controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Ischaemia-reperfusion injury

### **Interventions**

From induction of anaesthesia, patients were administered 250 ml of 2% taurolidine or normal saline twice daily intravenously for 3 doses in total.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Taurolidine

### **Primary outcome(s)**

Cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10), measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping

### **Key secondary outcome(s)**

1. CD11b and CD14 receptor expression, measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping
2. Respiratory burst and phagocytosis of circulating neutrophils, measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping
3. Plasma lipopolysaccharide (LPS), measured immediately pre-operatively, at aortic unclamping,

two, six and 24-hours post-unclamping

4. Arrhythmias, analysed intra-operatively and daily up until hospital discharge

5. Complications, analysed intra-operatively and daily up until hospital discharge

**Completion date**

31/12/2001

## **Eligibility**

**Key inclusion criteria**

1. Patients (aged greater than or equal to 18 years, either sex) undergoing elective coronary artery bypass grafting

2. Left ventricular ejection fraction greater than 30% (affects likelihood of developing infection post-operatively for various reasons including increased inotropic support requirements, longer intensive care unit [ICU] stay, delayed mobilisation, and delayed removal of urinary catheters and intravenous lines)

3. Normal pulmonary function tests (affects likelihood of developing respiratory complications post-operatively)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Patients with diabetes mellitus (affects likelihood of developing infection post-operatively)

2. Patients taking angiotensin-converting enzyme inhibitors (affects potential to reduce reperfusion injury by acting on leukocytes)

3. Patients taking steroids (more prone to developing infection)

4. Patients with chronic arrhythmias

**Date of first enrolment**

01/01/1999

**Date of final enrolment**

31/12/2001

## **Locations**

**Countries of recruitment**

Ireland

### Study participating centre

Department of Surgery

Cork

Ireland

-

## Sponsor information

### Organisation

Cork University Hospital (Ireland)

### ROR

<https://ror.org/04q107642>

## Funder(s)

### Funder type

Hospital/treatment centre

### Funder Name

Cork University Hospital (Ireland) - Department of Academic Surgery, University College Cork

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes